Alnylam Pharmaceuticals just delivered eye catching Q3 2026 numbers and the stock still sold off. Shares closed at US$165, about 5% lower on the day and down roughly one third over the past month even as reported basic earnings per share jumped to US$16.19 on quarterly revenue of US$1.46b.
Short term traders are reacting to the red on the screen. Long term holders are staring at a biotech with a reported trailing P/E near 8x and very high recent net margins and asking whether the market is mispricing a complex earnings story.
Do you like Alnylam Pharmaceuticals’ earnings power but feel uneasy about a biotech stock that can swing 30% in a month? If so, you may want to review our list of companies with strong profitability and sturdier balance sheets in the list of solid balance sheet and fundamentals stocks (25 results)
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025): US$1.46b vs. US$1.25b (higher year on year)
-
Net Income (Q3 2026 vs. Q3 2025): US$2,167.3m vs. US$251.1m (very large year on year increase, supported by non cash items)
-
Basic EPS (Q3 2026 vs. Q3 2025): US$16.19 vs. US$1.91 (very large year on year jump, heavily influenced by non cash earnings components)
-
Net Profit Margin, trailing 12 months (latest vs. prior year): 53.7% vs. 2.4% (margin much higher, includes significant non cash effects)
Tired of scrolling through walls of earnings tables and footnotes? See Alnylam Pharmaceuticals’ full financial picture with a clean, visual breakdown of its valuation in the company report for Alnylam Pharmaceuticals.
Alnylam earnings power backs RNAi growth story
Alnylam Pharmaceuticals just reported a significant revenue increase, with total sales and earnings both much higher than a year ago and TTR product revenue up more than 50%. That kind of top line and profit expansion supports the RNAi platform leader narrative. Cash and securities of US$3.6b provide room to continue funding late stage programs such as Nucresiran and brezosiran. Management is still emphasizing strong TTR cash flows funding the broader pipeline, which aligns with the idea of a commercial engine supporting multi asset optionality.
Earnings beat but execution and policy worries linger
The same Q3 2026 report also supports a more cautious view on Alnylam Pharmaceuticals. Shares fell about 5% on the day and are down roughly one third over 30 days despite the earnings jump. Management now guides TTR product sales to the low end of the US$4.2b to US$4.5b range and highlights slower than hoped AMVUTTRA demand, reimbursement uncertainty around the 340B rule, and ongoing legal investigations. These factors keep commercial execution and policy risk firmly in focus even alongside recent profitability.
